NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) EBIT : $-5.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is NovaBay Pharmaceuticals EBIT?

NovaBay Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-0.80 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. NovaBay Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 was -52.92%. NovaBay Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -101.17%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. NovaBay Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -100.42%.

NovaBay Pharmaceuticals EBIT Historical Data

The historical data trend for NovaBay Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovaBay Pharmaceuticals EBIT Chart

NovaBay Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-9.40

-6.43

-8.86

-7.68

-5.00

NovaBay Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-2.69	-1.73	-1.36	-1.12	-0.80

Competitive Comparison of NovaBay Pharmaceuticals's EBIT

For the Biotechnology subindustry, NovaBay Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovaBay Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NovaBay Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NovaBay Pharmaceuticals's EV-to-EBIT falls into.

NovaBay Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.00 Mil.

NovaBay Pharmaceuticals (AMEX:NBY) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

NovaBay Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-3.192 * ( 1 - 0% )	/	( (7.606	+	4.458)	/ 2 )
=	-3.192	/	6.032
=	-52.92 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	12.852	-	1.774	-	( 3.472	-	max(0, 4.571	-	8.214	+	3.472	))
=	7.606

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	9.034	-	1.7	-	( 3.13	-	max(0, 4.278	-	7.154	+	3.13	))
=	4.458

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

NovaBay Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-3.192	/	( ( (1.623 + max(1.926, 0))	+	(1.383 + max(1.378, 0)) )	/	2 )
=	-3.192	/	( ( 3.549	+	2.761 )	/	2 )
=	-3.192	/	3.155
=	-101.17 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.916	+	3.493	+	0.333)	-	(1.774	+	1.042	+	0)
=	1.926

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.759	+	2.877	+	0.388)	-	(1.7	+	0.946	+	0)
=	1.378

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

NovaBay Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-5.003	/	4.982
	=	-100.42 %

NovaBay Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of NovaBay Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NovaBay Pharmaceuticals Inc (AMEX:NBY) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

B9P:Germany

Address

2000 Powell Street, Suite 1150, Emeryville, CA, USA, 94608

Website

https://www.novabay.com

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare and skincare products. Its leading product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available direct to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.

Executives

Tommy Law	officer: Interim CFO	2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Jeffrey Kunin	officer: President, DERMAdoctor, LLC	4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Audrey Kunin	officer: Chief Product Officer	4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Justin Hall	officer: General Counsel	5980 HORTON STREET, SUITE 550, EMERYVILLE CA 94608
Yongxiang Zheng	director	NO.10, UNIT 1, LIJING VILLA, TIANZHU, SHUNYI DISTRICT, BEIJING F4 101316
Julie Garlikov	director	2420 17TH STREET, SUITE 220, DENVER CO 80202
Andrew D. Jones	officer: CFO and Treasurer	2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Mijia Wu	director	SUITE 6C, BLDG 3, YOU YOU CENTURY PLAZA, NO 428 YANG GAO SOUTH ROAD, SHANGHAI F4 CHINA
Jian Ping Fu	10 percent owner	LEVEL 1, BLDG 1, GREENWOOD BUSINESS PARK, 301 BURWOOD HWY, BURWOOD C3 3125
Wang Xu	officer: NEO - Sr Mgr and Controller	2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Swan Sit	director	95 JACKSON STREET, NEWTON MA 02459
Yenyou Zheng	director	1055 WEST HASTINGS STREET, SUITE 1980, VANCOUVER A1 V6E 2E9
Xiaopei Wang	director	2/44 FRANKLIN ROAD, DONCASTER EAST C3 3109
Jason Philip Raleigh	officer: Interim CFO and Treasurer	2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Pioneer Pharma (hong Kong) Co Ltd	10 percent owner	FLAT 2605, 26/F TRENDY CENTRE, 682 CASTLE PEAK ROAD, KOWLOON K3 000000